This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yoshida, K. Articles by Abe, K. Search for Related Content PubMed PubMed Citation Articles by Yoshida, K. Articles by Abe, K.

Hypertension, Vol 20, 292-297, Copyright © 1992 by American Heart Association

ARTICLES

Endothelin-1 augments pressor response to angiotensin II infusion in rats

K Yoshida, M Yasujima, M Kohzuki, M Kanazawa, K Yoshinaga and K Abe
Second Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.

To assess possible roles of endothelin in the regulation of blood pressure, we studied effects of a subpressor dose of endothelin-1 (3 micrograms/kg/day) on chronic blood pressure responses to infusion of angiotensin II and norepinephrine in rats. Rats were infused with angiotensin II at a subpressor dose (400 micrograms/kg/day i.p.) or with norepinephrine at a subpressor dose (360 micrograms/kg/day i.p.) for 6 days. Systolic blood pressure was significantly elevated during combined infusion of endothelin-1 and angiotensin II, whereas endothelin-1 alone or angiotensin II alone failed to induce any significant changes in systolic blood pressure compared with vehicle alone. This effect was sustained for the whole experimental period and was not associated with any significant changes in body weight, fluid intake, urine volume, or urinary electrolyte excretion. In contrast, combined infusion of endothelin-1 and norepinephrine failed to elevate systolic blood pressure, and no significant difference in systolic blood pressure was observed for the whole experimental period among the four groups of rats with endothelin-1 in combination with norepinephrine, endothelin-1 alone, norepinephrine alone, and vehicle alone. The present results indicate that angiotensin II and endothelin- 1, but not norepinephrine and endothelin-1, work synergistically to raise the blood pressure and also suggest the possibility that endothelin-1 may modulate blood pressure control.

This article has been cited by other articles:

				C.-C. Juan, T.-Y. Chuang, C.-C. Lien, Y.-J. Lin, S.-W. Huang, C. F. Kwok, and L.-T. Ho Leptin increases endothelin type A receptor levels in vascular smooth muscle cells Am J Physiol Endocrinol Metab, March 1, 2008; 294(3): E481 - E487. [Abstract] [Full Text] [PDF]

				C. Zeng, U. Hopfer, L. D. Asico, G. M. Eisner, R. A. Felder, and P. A. Jose Altered AT1 Receptor Regulation of ETB Receptors in Renal Proximal Tubule Cells of Spontaneously Hypertensive Rats Hypertension, October 1, 2005; 46(4): 926 - 931. [Abstract] [Full Text] [PDF]

				C.-C. Juan, Y.-W. Shen, Y. Chien, Y.-J. Lin, S.-F. Chang, and L.-T. Ho Insulin infusion induces endothelin-1-dependent hypertension in rats Am J Physiol Endocrinol Metab, November 1, 2004; 287(5): E948 - E954. [Abstract] [Full Text] [PDF]

				M. C. Kowala, N. Murugesan, J. Tellew, K. Carlson, H. Monshizadegan, C. Ryan, Z. Gu, B. Kane, L. Fadnis, R. A. Baska, et al. Novel Dual Action AT1 and ETA Receptor Antagonists Reduce Blood Pressure in Experimental Hypertension J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 275 - 284. [Abstract] [Full Text]

				A. Montanari, A. Biggi, N. Carra, M. Ziliotti, E. Fasoli, L. Musiari, P. Perinotto, and A. Novarini Endothelin-A Receptors Mediate Renal Hemodynamic Effects of Exogenous Angiotensin II in Humans Hypertension, October 1, 2003; 42(4): 825 - 830. [Abstract] [Full Text] [PDF]

				N. H.S. Kim and L. J. Rubin Endothelin in Health and Disease: Endothelin Receptor Antagonists in the Management of Pulmonary Artery Hypertension Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2002; 7(1): 9 - 19. [Abstract] [PDF]

				A. Montanari, N. Carra, P. Perinotto, V. Iori, E. Fasoli, A. Biggi, and A. Novarini Renal Hemodynamic Control by Endothelin and Nitric Oxide Under Angiotensin II Blockade in Man Hypertension, February 1, 2002; 39(2): 715 - 720. [Abstract] [Full Text] [PDF]

				A. Riggleman, J. Harvey, and C. Baylis Endothelin Mediates Some of the Renal Actions of Acutely Administered Angiotensin II Hypertension, July 1, 2001; 38(1): 105 - 109. [Abstract] [Full Text] [PDF]

				J. R. Ballew, S. W. Watts, and G. D. Fink Effects of Salt Intake and Angiotensin II on Vascular Reactivity to Endothelin-1 J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 345 - 350. [Abstract] [Full Text]

				P. T. Nowicki and L. A. Minnich Effects of systemic hypotension on postnatal intestinal circulation: role of angiotensin Am J Physiol Gastrointest Liver Physiol, February 1, 1999; 276(2): G341 - G352. [Abstract] [Full Text] [PDF]

				A. Lerman, J. C. Burnett Jr, S. T. Higano, L. J. McKinley, and D. R. Holmes Jr Long-term L-Arginine Supplementation Improves Small-Vessel Coronary Endothelial Function in Humans Circulation, June 2, 1998; 97(21): 2123 - 2128. [Abstract] [Full Text] [PDF]

				A. Herizi, B. Jover, N. Bouriquet, and A. Mimran Prevention of the Cardiovascular and Renal Effects of Angiotensin II by Endothelin Blockade Hypertension, January 1, 1998; 31(1): 10 - 14. [Abstract] [Full Text] [PDF]

				A. Lerman, D. R. Holmes Jr, M. R. Bell, K. N. Garratt, R. A. Nishimura, and J. C. Burnett Jr Endothelin in Coronary Endothelial Dysfunction and Early Atherosclerosis in Humans Circulation, November 1, 1995; 92(9): 2426 - 2431. [Abstract] [Full Text]